|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
|---|---|
| Information provided by: | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| ClinicalTrials.gov Identifier: | NCT00679692 |
Purpose
BACKGROUND The insulin-like growth factor system (IGFs) plays an important role in cell growth and differentiation. Nevertheless, the roles played by insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3) and human growth hormone (HGH) in the progression of chronic liver disease remain to be elucidated and investigated.
METHODS The subjects in the present study included 60 healthy controls, 30 hepatitis patients, 60 liver cirrhosis patients and 60 untreated hepatocellular carcinoma patients. Blood was drawn by venipuncture into Venoject tubes. To find the possible correlations between liver damage and IGFs, serum IGF-1, GH, IGFBP-3 concentration and related biochemical parameters were measured. We used immunoradiometric assay to determine the levels of IGF-1, HGH and IGFBP-3 in serum.
| Condition |
|---|
|
Hepatitis Liver Cirrhosis Hepatocellular Carcinoma |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Insulin-Like Growth Factor-1,Insulin-Like Growth Factor Binding Protein-3 and Human Growth Hormone in Serum of Patients With Chronic Liver Disease and Possible Clinical Applications. |
serum
| Enrollment: | 210 |
| Study Start Date: | September 2006 |
| Study Completion Date: | March 2008 |
| Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
3:
three arms for study
|
healthy controls:one blood sample (7.5 cc) hepatitis: three blood samples, at admission, at 3rd and 7-10th day of admission liver cirrhosis: two blood samples, at 1-2 years interval (7.5 cc/each session) hepatocellular carcinoma: three blood samples, before, 1 day after and at the 7th day of transcatheter arterial chembolizatiom
Eligibility| Ages Eligible for Study: | 30 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Acute hepatitis liver cirrhosis hepatocellular carcinoma
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Taiwan | |
| Division of Radio immunoassay lab,Department of Nuclear Medical University Hospital,No.100 Tzyou 1st Road | |
| Kaohsiung, Taiwan | |
| Principal Investigator: | chiou m Lin, Ms | Kaohsiung Medical University |
More Information
| Responsible Party: | Kaoshing Medical University Chung-Ho Memorial Hospital ( Kaoshing Medical University Chung-Ho Memorial Hospital ) |
| Study ID Numbers: | KMUH-IRB-950123, KMUH-IRB-950123 |
| Study First Received: | May 15, 2008 |
| Last Updated: | May 16, 2008 |
| ClinicalTrials.gov Identifier: | NCT00679692 |
| Health Authority: | Taiwan: Institutional Review Board |
|
GH,IGF-1, IGFBP-3 |
|
Liver Diseases Digestive System Neoplasms Carcinoma, Hepatocellular Fibrosis Liver neoplasms Liver Cirrhosis Insulin Carcinoma |
Hepatitis Liver Neoplasms Digestive System Diseases Gastrointestinal Neoplasms Adenocarcinoma Neoplasms, Glandular and Epithelial Hepatocellular carcinoma |
|
Neoplasms Pathologic Processes Neoplasms by Site Neoplasms by Histologic Type |
